Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/4858
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tufan, Ahmet Çevik | - |
dc.contributor.author | Satıroğlu-Tufan, Naciye Lale | - |
dc.date.accessioned | 2019-08-16T11:38:04Z | |
dc.date.available | 2019-08-16T11:38:04Z | |
dc.date.issued | 2005 | - |
dc.identifier.issn | 1568-0096 | - |
dc.identifier.uri | https://hdl.handle.net/11499/4858 | - |
dc.identifier.uri | https://doi.org/10.2174/1568009054064624 | - |
dc.description.abstract | Angiogenesis, the formation of new blood vessels, is essential for tumor growth, progression and metastasis. The development of agents that target tumor vasculature is ultimately dependent on the availability of appropriate preclinical screening assays. The chorioallantoic membrane (CAM) assay is well established and widely used as a model to examine angiogenesis, and anti-angiogenesis. This review 1) summarizes the currently used angiogenesis assays and the importance of CAM model among them; 2) summarizes the current knowledge about the development and structure of the CAM's capillary bed; 3) reports findings regarding the role played by molecular signaling pathways in angiogenesis process; 4) discusses the use, advantages and limitations of the CAM as a model for studying tumor angiogenesis and invasiveness, as well as development of angiogenic and/or anti-angiogenic agents; 5) discusses the importance of standardization of the major methodologies for all aspects of the use of the CAM in angiogenesis-related studies; 6) and finally, summarizes major findings regarding the agents developed by the use of CAM model in the study of tumor angiogenesis, invasion and development of anti-angiogenic agents. © 2005 Bentham Science Publishers Ltd. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Current Cancer Drug Targets | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | 1,4 phenylenebis(methylene)selenocyanate | en_US |
dc.subject | acetylsalicylic acid | en_US |
dc.subject | alpha cyclodextrin | en_US |
dc.subject | alpha thymosin peptide | en_US |
dc.subject | amiloride | en_US |
dc.subject | angiogenesis inhibitor | en_US |
dc.subject | angiogenin antibody | en_US |
dc.subject | angiopoietin receptor | en_US |
dc.subject | angiostatin | en_US |
dc.subject | angiotensinogen | en_US |
dc.subject | angiotensinogen derivative | en_US |
dc.subject | anthracycline derivative | en_US |
dc.subject | apomorphine | en_US |
dc.subject | arylsulfatase inhibitor | en_US |
dc.subject | basic fibroblast growth factor antibody | en_US |
dc.subject | beta cyclodextrin | en_US |
dc.subject | bleomycin | en_US |
dc.subject | carbohydrate derivative | en_US |
dc.subject | cell adhesion molecule antagonist | en_US |
dc.subject | cortisone | en_US |
dc.subject | cyclosporin | en_US |
dc.subject | cytokine | en_US |
dc.subject | doxorubicin | en_US |
dc.subject | endostatin | en_US |
dc.subject | fenretinide | en_US |
dc.subject | fibroblast growth factor | en_US |
dc.subject | fibroblast growth factor 2 | en_US |
dc.subject | gm 1474 | en_US |
dc.subject | goniodomin A | en_US |
dc.subject | heparan sulfate | en_US |
dc.subject | heparanase inhibitor | en_US |
dc.subject | heparin | en_US |
dc.subject | homocysteine | en_US |
dc.subject | hyaluronic acid binding protein | en_US |
dc.subject | indinavir | en_US |
dc.subject | indole derivative | en_US |
dc.subject | interleukin 2 | en_US |
dc.subject | kininogen | en_US |
dc.subject | kininogen derivative | en_US |
dc.subject | kininostat | en_US |
dc.subject | matrix metalloproteinase inhibitor | en_US |
dc.subject | metastatin | en_US |
dc.subject | microsomal aminopeptidase inhibitor | en_US |
dc.subject | mitogen activated protein kinase p38 | en_US |
dc.subject | monoclonal antibody | en_US |
dc.subject | motuporanine | en_US |
dc.subject | nitric oxide | en_US |
dc.subject | ornithine decarboxylase inhibitor | en_US |
dc.subject | pentosan polysulfate | en_US |
dc.subject | peptide derivative | en_US |
dc.subject | platelet derived growth factor | en_US |
dc.subject | protamine | en_US |
dc.subject | protamine sulfate | en_US |
dc.subject | proteasome inhibitor | en_US |
dc.subject | protein tyrosine kinase inhibitor | en_US |
dc.subject | prothrombin | en_US |
dc.subject | purine derivative | en_US |
dc.subject | retinoid | en_US |
dc.subject | ruthenium red derivative | en_US |
dc.subject | saquinavir | en_US |
dc.subject | scatter factor | en_US |
dc.subject | somatostatin | en_US |
dc.subject | somatostatin derivative | en_US |
dc.subject | spironolactone | en_US |
dc.subject | squalamine | en_US |
dc.subject | steroid | en_US |
dc.subject | stromelysin | en_US |
dc.subject | sulindac | en_US |
dc.subject | suramin | en_US |
dc.subject | suramin derivative | en_US |
dc.subject | tamoxifen | en_US |
dc.subject | thalidomide | en_US |
dc.subject | thrombocyte factor 4 | en_US |
dc.subject | thymidine phosphorylase inhibitor | en_US |
dc.subject | titanocene dichloride | en_US |
dc.subject | transforming growth factor alpha | en_US |
dc.subject | transforming growth factor beta | en_US |
dc.subject | u 995 | en_US |
dc.subject | unclassified drug | en_US |
dc.subject | vasculotropin | en_US |
dc.subject | vasculotropin antibody | en_US |
dc.subject | vasculotropin diphtheria toxin conjugate | en_US |
dc.subject | vasculotropin receptor 2 | en_US |
dc.subject | angiogenesis | en_US |
dc.subject | apoptosis | en_US |
dc.subject | assay | en_US |
dc.subject | cancer invasion | en_US |
dc.subject | capillary | en_US |
dc.subject | cell culture | en_US |
dc.subject | cell growth | en_US |
dc.subject | cell migration | en_US |
dc.subject | cell proliferation | en_US |
dc.subject | cell viability | en_US |
dc.subject | chemokinesis | en_US |
dc.subject | chick embryo | en_US |
dc.subject | chorioallantois | en_US |
dc.subject | cost effectiveness analysis | en_US |
dc.subject | DNA synthesis | en_US |
dc.subject | drug mechanism | en_US |
dc.subject | embryo development | en_US |
dc.subject | endothelium cell | en_US |
dc.subject | fetus membrane | en_US |
dc.subject | in vivo study | en_US |
dc.subject | mesoderm | en_US |
dc.subject | metastasis | en_US |
dc.subject | model | en_US |
dc.subject | morphometrics | en_US |
dc.subject | nonhuman | en_US |
dc.subject | organ culture | en_US |
dc.subject | protein family | en_US |
dc.subject | protein function | en_US |
dc.subject | review | en_US |
dc.subject | scoring system | en_US |
dc.subject | standardization | en_US |
dc.subject | tumor growth | en_US |
dc.subject | tumor vascularization | en_US |
dc.subject | validation process | en_US |
dc.subject | Angiogenesis Inhibitors | en_US |
dc.subject | Animals | en_US |
dc.subject | Chick Embryo | en_US |
dc.subject | Chorioallantoic Membrane | en_US |
dc.subject | Drug Evaluation, Preclinical | en_US |
dc.subject | Humans | en_US |
dc.subject | Models, Biological | en_US |
dc.subject | Neoplasm Invasiveness | en_US |
dc.subject | Neoplasms | en_US |
dc.subject | Neovascularization, Pathologic | en_US |
dc.title | The chick embryo chorioallantoic membrane as a model system for the study of tumor angiogenesis, invasion and development of anti-angiogenic agents | en_US |
dc.type | Review | en_US |
dc.identifier.volume | 5 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | 249 | |
dc.identifier.startpage | 249 | en_US |
dc.identifier.endpage | 266 | en_US |
dc.authorid | 0000-0001-9399-0960 | - |
dc.identifier.doi | 10.2174/1568009054064624 | - |
dc.relation.publicationcategory | Diğer | en_US |
dc.identifier.pmid | 15975046 | en_US |
dc.identifier.scopus | 2-s2.0-21344456550 | en_US |
dc.identifier.wos | WOS:000230100100002 | en_US |
dc.identifier.scopusquality | Q1 | - |
dc.owner | Pamukkale_University | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.openairetype | Review | - |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | 14.03. Basic Medical Sciences | - |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
CORE Recommender
SCOPUSTM
Citations
116
checked on Dec 14, 2024
WEB OF SCIENCETM
Citations
103
checked on Dec 19, 2024
Page view(s)
44
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.